Complement inhibition by eculizumab
New therapeutic approach in myasthenia gravis and neuromyelitis optica
Complement inhibition by eculizumab
New therapeutic approach in myasthenia gravis and neuromyelitis optica
Focus on myasthenia gravis and neuromyelitis optica, two rare autoimmune neurological diseases sharing a pathogenetic mechanism involving the complement system. The protagonist of the 5 video interviews carried out on the occasion of the 52nd Congress of the Italian Society of Neurology is the monoclonal antibody Eculizumab which bases its efficacy on the inhibition of the complement and on the rapidity of the therapeutic response. Among the topics addressed, the comparison between new therapies and traditional treatments, diagnostic difficulties, drug resistance and side effects.
Focus on myasthenia gravis and neuromyelitis optica, two rare autoimmune neurological diseases sharing a pathogenetic mechanism involving the complement system. The protagonist of the 5 video interviews carried out on the occasion of the 52nd Congress of the Italian Society of Neurology is the monoclonal antibody Eculizumab which bases its efficacy on the inhibition of the complement and on the rapidity of the therapeutic response. Among the topics addressed, the comparison between new therapies and traditional treatments, diagnostic difficulties, drug resistance and side effects.
interviews
Paradigm shift in the treatment of myasthenia gravis
it
Dr. Francesco Saccà
Treatment of myasthenia gravis: the still open challenges
it
Dr. Michelangelo Maestri
Neuromyelitis optica and multiple sclerosis, similarities and differences
it
Dr. Lucia Moiola
Neuromyelitis optica in the light of new treatments
it
Dr. Carla Tortorella
Eculizumab: what therapeutic innovations in myasthenia gravis
it
Dr. Vincenzo Di Stefano